An observational study in Obesity & Overweight and Prediabetes / Type 2 Diabetes, sponsored by Hong Kong Baptist University. Not yet recruiting at 2 sites in 2 countries. Open to participants aged 40 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-30.
Sponsored by Hong Kong Baptist University · Observational
Among 597 studies in Obesity with a site in China — 220 open to participants now, 282 under way, 68 of them phase 3. Obesity · China.
Among the 597 studies in Obesity with a site in China, this one is the 77th largest by planned enrollment of the 98 observational ones that give a count, is one of 131 that started in 2026, is one of 98 observational ones, reaches primary completion later than 245 of the 280 other live ones, and was the 529th registered.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
Browse Obesity studies →220 of the 597 studies in Obesity with a site in China are open now. Recruiting first, the newest first:
The First Hospital of Jilin University · Sites in China
Ages 18–65
Pfizer · Sites in China
Ages 18+
Eli Lilly and Company · Sites in China, United States, Brazil and 7 more countries
Ages 18+
The United Bio-Technology (Hengqin) Co., Ltd. · Sites in China
Ages 18–55
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,336 Obesity studies recruiting now, 377 (28%) set no upper age limit and 856 (64%) stop at 75 or younger; 168 take children under 18; 491 take healthy volunteers.
This study: 40 Years to 59 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
597 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 100 · Phase 2 70 · Phase 3 108 · Phase 4 28
First in 1997; this study’s year is marked. 131 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is close to the median of 114 across 2,154 observational studies indexed under Obesity.
Median enrollment 120 across the 499 interventional studies, 310 across the 98 observational. Of the 238 that completed or were terminated, 13 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
238 of 597 have an industry lead sponsor. The 10 most frequent:
Hong Kong Baptist University is the lead sponsor of 84 studies on the registry; 23 are open to participants now.
Hong Kong Baptist University has 4 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
101 of the studies in Obesity with a site in China that are under way reach primary completion within a year, 20 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06974851Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity | 2026-12 |
| NCT06994650Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy | 2026-12 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07285902Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity | 2027-03 |
Among the 597 studies in Obesity with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The prevalence of diabetes in China is a significant concern. In 2019, 116.4 million adults were living with diabetes, a number expected to climb to 147.2 million by 2045. Type 2 diabetes (T2D) constitutes 95% of these cases . In Hong Kong, T2D affects an estimated 700,000 people, with prevalence keeps rising. Epidemiology data clearly show that obesity and T2D are closely associated. A previous study conducted by the investigators found that integrin-β2 protein levels are significantly increased in the circulating small extracellular vesicles (sEVs) of obese/overweight individuals.
Given the well-known association between integrin/ECM and the development of insulin resistance, The study hypothesis is that integrin-β2 and ECM1 proteins in the circulating sEVs can be used for the early detection of obese individuals at risk for T2D.This proposed study is critical to provide supporting data for the implementation of a subsequent prospective cohort study to validate whether integrin β2/ECM1 proteins in circulating sEVs can be used for the early detection of obese individuals at risk for T2D.
Obesity is strongly associated with insulin resistance, prediabetes, and type 2 diabetes. Current screening approaches for prediabetes and type 2 diabetes mainly rely on glucose-related measurements, including fasting plasma glucose, OGTT, and HbA1c. These measurements are useful for identifying abnormal glucose regulation, but additional blood-based biomarkers may help identify obese individuals who are at higher risk of type 2 diabetes before or during the early stage of glucose dysregulation.
Small extracellular vesicles are circulating membrane-bound vesicles that carry proteins and other biomolecules. Previous work from the study team showed that integrin-β2 and extracellular matrix protein 1 were increased in circulating small extracellular vesicles from obese or overweight individuals. Given the well-known association between integrin/ECM and the development of insulin resistance, the study hypothesize is that integrin-β2 and ECM1 proteins in the circulating sEVs can be used for the early detection of obese individuals at risk for T2D.
This is an observational biomarker study in human participants. After informed consent, participants will undergo body mass index assessment and fasting blood collection after an overnight fast. Fasting plasma glucose and HbA1c will be measured by a registered clinical laboratory. BMI and glucose-related testing results, participants will be assigned to comparison groups including non-overweight/non-obese individuals, overweight/obese individuals, non-overweight/non-obese individuals with prediabetes or type 2 diabetes and overweight/obese individuals with prediabetes or type 2 diabetes.
Blood samples will be used for isolation of circulating small extracellular vesicles according to established laboratory protocols. The levels of integrin-β2, extracellular matrix protein 1, and other candidate small extracellular vesicle proteins will be measured. Protein levels will be compared across the study groups to determine whether these circulating small extracellular vesicle protein signatures are specifically associated with obesity-related prediabetes or type 2 diabetes.
The planned sample size for the human observational component is 120 participants, with 30 participants in each of the four groups. The sample size was calculated using G*Power to compare protein expression levels across four groups, assuming a medium effect size of 0.25, an alpha level of 0.05, and 80% statistical power. Participants will be assigned study codes. The code identifier file and study data will be stored separately in password-protected computers and will be accessible only to research personnel. Data will be deleted five years after study completion.
The main purpose of this study is to examine whether elevated integrin-β2 and /or ECM1 (and the protein candidates in contingency plan) in circulating sEVs is specific for obesity-associated T2D.This proposed study is critical to provide supporting data for the implementation of a subsequent prospective cohort study to validate whether integrin β2/ECM1 proteins in circulating sEVs can be used for the early detection of obese individuals at risk for T2D.
The study population will consist of Hong Kong residents aged 40 to 59 years recruited from the Hong Kong Baptist University Mr. \& Mrs. Chan Hon Yin Chinese Medicine Specialty Clinic and Good Clinical Practice Centre, as well as through recruitment posters and social media announcements. Participants will be classified into four groups according to BMI and glycemic status: non-overweight/non-obese participants without prediabetes or type 2 diabetes, overweight/obese participants without prediabetes or type 2 diabetes, non-overweight/non-obese participants with prediabetes or type 2 diabetes, and overweight/obese participants with prediabetes or type 2 diabetes. Approximately 30 participants will be enrolled in each group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with a BMI of 18.8 to 22.9 who do not meet the study criteria for prediabetes or type 2 diabetes.
Participants who are overweight or obese, with a BMI of 23.0 or higher, and who do not meet the study criteria for prediabetes or type 2 diabetes
Participants with a BMI of 18.8 to 22.9, who meet the study criteria for prediabetes or type 2 diabetes based on fasting plasma glucose and HbA1c measurements.
Participants who are overweight or obese, with a BMI of 23.0 or higher, and who meet the study criteria for prediabetes or type 2 diabetes based on fasting plasma glucose and HbA1c measurements.
Integrin-β2, ECM1 (and the protein candidates in our contingency plan) in circulating sEVs
The protein level of integrin-β2, ECM1 (and the protein candidates in our contingency plan) in circulating sEVs will be measured. Protein levels will be compared among the four groups.
Time frame: At enrollment (single fasting blood collection)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Sep 2028, 23 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hong Kong Baptist University